
    
      This single arm, Phase II study will examine the efficacy and safety of the novel
      Proteasome/IMiD combination of Ixazomib 4mg days 1, 8, 15, Pomalidomide 4 mg days 1-21,
      Dexamethasone 20 mg days 1, 8, 15, and 22 of a 28 day cycle, in relapse patients. The long
      term aim being to develop a backbone regimen to which future novel targeted treatments may be
      added as part of a personalized medicine approach.
    
  